Literature DB >> 19412723

Debilitating consequences of drooling.

B R Bloem, J G Kalf, P C M van de Kerkhof, M J Zwarts.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19412723      PMCID: PMC2721959          DOI: 10.1007/s00415-009-5144-0

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


× No keyword cloud information.
A 71-year-old man with a 13-year history of idiopathic Parkinson’s disease (PD) was referred to us because of severe and intractable drooling. His complaints started 4 years earlier with nocturnal drooling, but this had progressed to profuse drooling throughout the day. By that time he also suffered from severely impaired swallowing and severe hypokinetic dysarthria. The corners of his mouth were persistently wet, and this had produced a debilitating dermatitis in the perioral region, which is illustrated in Fig. 1. At investigation we observed erythematous plaques, in part sharply demarcated. The lesions showed some rhagades and mild scaling. Moreover, despite use of handkerchiefs, saliva was constantly dripping onto the patient’s clothes and feet, destroying the leather of his shoes and necessitating him to purchase new shoes every 3 months. Symptomatic treatment with anticholinergics had been tried, but this was stopped because of systemic side effects. Injection of botulinum toxin into the submandibular and parotid glands effectively suppressed saliva production, and the perioral skin lesions improved considerably.
Fig. 1

Prior to botulinum toxin injections into the salivary glands, there was a marked perioral dermatitis

Prior to botulinum toxin injections into the salivary glands, there was a marked perioral dermatitis This case history underscores that drooling can have a tremendous impact on the quality of life of affected patients [3]. The exact pathophysiology remains to be determined, but is more likely related to reduced automatic swallowing frequency than to increased production of saliva [4]. Various symptomatic treatments are available, aiming either to reduce saliva production (botulinum toxin, anticholinergics, or radiotherapy over the salivary glands) or to improve the quality and frequency of swallowing [1, 2].
  4 in total

1.  Impact of drooling in Parkinson's disease.

Authors:  Johanna G Kalf; Anne M Smit; Bastiaan R Bloem; Machiel J Zwarts; Marten Munneke
Journal:  J Neurol       Date:  2007-08-02       Impact factor: 4.849

2.  Quantitative study of salivary secretion in Parkinson's disease.

Authors:  Omar R Tumilasci; M G Cersósimo; Juan E Belforte; Federico E Micheli; Eduardo E Benarroch; Jorge H Pazo
Journal:  Mov Disord       Date:  2006-05       Impact factor: 10.338

3.  Botulinum toxin A for drooling in Parkinson's disease: a pilot study to compare submandibular to parotid gland injections.

Authors:  Johanna G Kalf; Anne M Smit; Bastiaan R Bloem; Machiel J Zwarts; Wim M Mulleners; Marten Munneke
Journal:  Parkinsonism Relat Disord       Date:  2007-03-26       Impact factor: 4.891

Review 4.  Sialorrhea in Parkinson's disease: a review.

Authors:  Kelvin L Chou; Marian Evatt; Vanessa Hinson; Katie Kompoliti
Journal:  Mov Disord       Date:  2007-12       Impact factor: 10.338

  4 in total
  4 in total

Review 1.  Drooling in Parkinson's disease: a review.

Authors:  Prachaya Srivanitchapoom; Sanjay Pandey; Mark Hallett
Journal:  Parkinsonism Relat Disord       Date:  2014-08-27       Impact factor: 4.891

2.  Diurnal and nocturnal drooling in Parkinson's disease.

Authors:  J G Kalf; B R Bloem; M Munneke
Journal:  J Neurol       Date:  2011-06-23       Impact factor: 4.849

Review 3.  The Skin and Parkinson's Disease: Review of Clinical, Diagnostic, and Therapeutic Issues.

Authors:  Matej Skorvanek; Kailash P Bhatia
Journal:  Mov Disord Clin Pract       Date:  2016-09-08

Review 4.  Oral Health Disorders in Parkinson's Disease: More than Meets the Eye.

Authors:  Manon Auffret; Vincent Meuric; Emile Boyer; Martine Bonnaure-Mallet; Marc Vérin
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.